Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 3/13/2025 | $14.00 | Neutral → Buy | Chardan Capital Markets |
| 12/17/2024 | Buy → Neutral | H.C. Wainwright | |
| 12/11/2024 | Buy → Neutral | Chardan Capital Markets | |
| 12/11/2024 | Overweight → Underweight | Morgan Stanley | |
| 12/10/2024 | Buy → Hold | D. Boral Capital | |
| 12/6/2024 | $45.00 | Buy | ROTH MKM |
| 12/5/2024 | $42.00 | Buy | H.C. Wainwright |
| 9/18/2024 | $55.00 | Buy | Chardan Capital Markets |
A new batch of neflamapimod capsules led to increased plasma drug concentrations and demonstrated improvement (p<0.001 vs. old capsules; p=0.003 vs. placebo) on the primary outcome measure, change from baseline in Clinical Dementia Rating Sum of Boxes (CDR-SB) Improvement (p=0.035 against either old capsules or placebo) also demonstrated on the Alzheimer's Disease Cooperative Study - Clinical Global Impression of Change (CGIC) Compared to either old capsules or placebo, a lower incidence of falls was seen in participants receiving study drug from the new batch of capsules during the extension phase Company to host investor webcast at 5:00 PM ET today to discuss results BOSTON, March 10,
— Data from the first 16 weeks of the open-label extension phase of the RewinD-LB trial are expected in 1Q 2025 and will include data from participants who have received capsules from a more recently manufactured batch of neflamapimod — — Pharmacokinetic data obtained in a food-effect study in healthy volunteers in 4Q 2024 indicates that the new capsules achieved targeted mean plasma concentrations — — Within-subject comparison of certain participants who received older capsules during the double-blind phase of the RewinD-LB trial and new capsules in the open-label extension phase indicated that participants receiving newer batch capsules, on average, achieved targeted plasma concentration
BOSTON, Jan. 29, 2025 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ:CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders, today announced that topline results from the Phase 2b RewinD-LB study will be presented at the 8th International Lewy Body Dementia Conference (ILBDC), being held in Amsterdam, on January 31, 2025. The initial topline results for the Phase 2b study of neflamapimod in dementia with Lewy bodies (DLB) were previously disclosed on December 10, 2024 and are available here. Details of the ILBDC presentation are as follow: Abstract Title: Efficacy and safety results of the RewinD-LB phase 2b clinical trial of neflamapimod in deme
A new batch of neflamapimod capsules led to increased plasma drug concentrations and demonstrated improvement (p<0.001 vs. old capsules; p=0.003 vs. placebo) on the primary outcome measure, change from baseline in Clinical Dementia Rating Sum of Boxes (CDR-SB) Improvement (p=0.035 against either old capsules or placebo) also demonstrated on the Alzheimer's Disease Cooperative Study - Clinical Global Impression of Change (CGIC) Compared to either old capsules or placebo, a lower incidence of falls was seen in participants receiving study drug from the new batch of capsules during the extension phase Company to host investor webcast at 5:00 PM ET today to discuss results BOSTON, March 10,
Chardan Capital Markets upgraded CervoMed from Neutral to Buy and set a new price target of $14.00
H.C. Wainwright downgraded CervoMed from Buy to Neutral
Chardan Capital Markets downgraded CervoMed from Buy to Neutral
4 - CervoMed Inc. (0001053691) (Issuer)
4 - CervoMed Inc. (0001053691) (Issuer)
4 - CervoMed Inc. (0001053691) (Issuer)
SC 13G - CervoMed Inc. (0001053691) (Subject)
SC 13G - CervoMed Inc. (0001053691) (Subject)
SC 13G/A - CervoMed Inc. (0001053691) (Subject)
4 - CervoMed Inc. (0001053691) (Issuer)
BOSTON, May 20, 2024 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ:CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders, today announced the appointment of William (Bill) Elder as Chief Financial Officer, effective June 1, 2024. Mr. Elder will continue to serve as General Counsel and Corporate Secretary. He will succeed William Tanner who has served as Chief Financial Officer to CervoMed and its predecessor, EIP Pharma, since September 2022. Mr. Tanner will continue as a consultant to CervoMed following the transition. "Bill's deep biopharmaceutical and financial expertise and strong track record of enhancing operational capabilities makes him
- Announced private placement of up to $149.4 million led by RA Capital Management with participation from Armistice Capital, Special Situations Funds and Soleus Capital; pro forma cash and cash equivalents from upfront proceeds expected to provide runway through the end of 2025 - CervoMed on track to complete enrollment in 2Q 2024 in its RewinD-LB Phase 2b clinical trial evaluating neflamapimod in patients with dementia with Lewy bodies (DLB); topline data expected in 4Q 2024 - Integrated summary of results from AscenD-LB Phase 2a trial published in peer-reviewed journal and presentations at a major scientific conference further inform on the potential of neflamapimod in DLB and proba
Dr. Boger is the founder, and retired CEO and Board Chair, of Vertex Pharmaceuticals CervoMed on track to complete enrollment in 1H 2024 in its RewinD-LB Phase 2b clinical trial evaluating neflamapimod in patients with dementia with Lewy bodies; topline data expected in 2H 2024 BOSTON, Feb. 07, 2024 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ:CRVO), a clinical-stage company developing treatments for degenerative diseases of the brain, today announced the appointment of Joshua Boger, Ph.D., to its Board of Directors (Board) and as Chair of the Board. Dr. Boger is an innovative scientist and highly successful business executive who brings extensive drug development and biopharmaceutical comp
8-K - CervoMed Inc. (0001053691) (Filer)
8-K - CervoMed Inc. (0001053691) (Filer)
8-K - CervoMed Inc. (0001053691) (Filer)